168 related articles for article (PubMed ID: 38456650)
1. Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas.
Shang S; Yang H; Chen M; Wu J; Shi X; Li X; Feng N; Zheng Z; Liu H; Zhang Y
J Int Med Res; 2024 Mar; 52(3):3000605241233166. PubMed ID: 38456650
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
3. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.
Janicki L; Patel A; Jendrzejewski J; Hellmann A
Front Endocrinol (Lausanne); 2023; 14():1273498. PubMed ID: 38047109
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
6. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
7. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
8. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis.
Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W
J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234
[TBL] [Abstract][Full Text] [Related]
9. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
10. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
12. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
13. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
[TBL] [Abstract][Full Text] [Related]
14. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma].
Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160
[No Abstract] [Full Text] [Related]
16. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
17. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
20. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
